Recently, RRM2 (Ribonucleotide Reductase Regulatory TP53 Inducible Subunit M2B) was discovered as a ferroptosis-related tumor biomarker in liver cancer; indeed, Tang et al. (2021a) demonstrated its anti-ferroptotic activity via a sustained GSH production. This evidence concerns the gene RRM2 and neoplasm.